RxDoctor Payments Data

Lauren Oliver, DO

Plastic and Reconstructive Surgery · Concord, NHNPI 1578898201

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,532 of the $6,684 with a category attached, or 82.8%. 22 manufacturers reported payments, led by Axogen at 30.7% of the total. Reporting peaked in 2023 at $2,446 and has fallen 93.9% since, to $148 in 2024.

$6,684in general payments, 2019–2025

Across 104 payments — averaging $64.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axogen$2K
  • Integra Lifesciences Corporation$1K
  • Medical Device Business Services, Inc.$591
  • Mentor Worldwide LLC$513
  • AbbVie$498
  • TELA Bio, Inc.$316
  • plus $1K from 16 others

What the payments were for

  • Travel & lodging$1,15117%
  • Food & beverage$5,53283%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few plastic and reconstructive surgery providers in New Hampshireto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$52,512
Medicare patients
97
Services billed
229

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Celecoxib25$287
Cephalexin43$183
Clindamycin Hcl14$124

Paid to pharmacies, not to this prescriber.

Other plastic and reconstructive surgery in Concord

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →